• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcmPermissionsJournals.ASM.orgJournalJCM ArticleJournal InfoAuthorsReviewers
J Clin Microbiol. Dec 1996; 34(12): 3031–3034.
PMCID: PMC229454

In vitro susceptibility testing and DNA typing of Saccharomyces cerevisiae clinical isolates.

Abstract

Saccharomyces spp. are widely distributed in nature and may colonize the normal human gastrointestinal tract. Although Saccharomyces cerevisiae isolates have been previously considered nonpathogenic, they appear to be increasingly associated with infections in immunocompromised or otherwise debilitated patients. The antifungal susceptibility and epidemiology of S. cerevisiae are poorly defined at present. A series of 76 isolates (mostly stool surveillance and throat swab isolates) from 70 bone marrow transplant patients hospitalized at two different medical centers were characterized by antifungal susceptibility testing and restriction endonuclease analysis of chromosomal DNA. For DNA typing, digestion with NotI followed by pulsed-field gel electrophoresis was applied. Typing results revealed 62 distinct DNA types among the 76 clinical isolates. Despite this genomic diversity, clusters of identical isolates were identified among different patients hospitalized concurrently in the same unit, indicating possible nosocomial transmission. The MICs of amphotericin B, 5-fluorocytosine, fluconazole, and itraconazole were determined by a broth microdilution method, as recommended by the National Committee for Clinical Laboratory Standards. The MICs at which 90% of the strains were inhibited were as follows: amphotericin B, 1.0 micrograms/ml; 5-fluorocytosine, 0.25 micrograms/ml; fluconazole, 8.0 micrograms/ml; and itraconazole, 1.0 micrograms/ml. The relative resistance of S. cerevisiae to fluconazole and itraconazole may promote the emergence of this species as a pathogen among immunosuppressed patients.

Full Text

The Full Text of this article is available as a PDF (203K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Anaissie E, Bodey GP, Kantarjian H, Ro J, Vartivarian SE, Hopfer R, Hoy J, Rolston K. New spectrum of fungal infections in patients with cancer. Rev Infect Dis. 1989 May-Jun;11(3):369–378. [PubMed]
  • Aucott JN, Fayen J, Grossnicklas H, Morrissey A, Lederman MM, Salata RA. Invasive infection with Saccharomyces cerevisiae: report of three cases and review. Rev Infect Dis. 1990 May-Jun;12(3):406–411. [PubMed]
  • Cimolai N, Gill MJ, Church D. Saccharomyces cerevisiae fungemia: case report and review of the literature. Diagn Microbiol Infect Dis. 1987 Oct;8(2):113–117. [PubMed]
  • Clemons KV, McCusker JH, Davis RW, Stevens DA. Comparative pathogenesis of clinical and nonclinical isolates of Saccharomyces cerevisiae. J Infect Dis. 1994 Apr;169(4):859–867. [PubMed]
  • Dougherty SH, Simmons RL. Postoperative peritonitis caused by Saccharomyces cerevisiae. Arch Surg. 1982 Feb;117(2):248–248. [PubMed]
  • Kiehn TE, Edwards FF, Armstrong D. The prevalence of yeasts in clinical specimens from cancer patients. Am J Clin Pathol. 1980 Apr;73(4):518–521. [PubMed]
  • McCusker JH, Clemons KV, Stevens DA, Davis RW. Saccharomyces cerevisiae virulence phenotype as determined with CD-1 mice is associated with the ability to grow at 42 degrees C and form pseudohyphae. Infect Immun. 1994 Dec;62(12):5447–5455. [PMC free article] [PubMed]
  • Nielsen H, Stenderup J, Bruun B. Fungemia with Saccharomycetaceae. Report of four cases and review of the literature. Scand J Infect Dis. 1990;22(5):581–584. [PubMed]
  • Oriol A, Ribera JM, Arnal J, Milla F, Batlle M, Feliu E. Saccharomyces cerevisiae septicemia in a patient with myelodysplastic syndrome. Am J Hematol. 1993 Aug;43(4):325–326. [PubMed]
  • Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995 Jan;39(1):1–8. [PMC free article] [PubMed]
  • Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi RN, Kauffman CA. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med. 1994 Oct;97(4):339–346. [PubMed]
  • Sethi N, Mandell W. Saccharomyces fungemia in a patient with AIDS. N Y State J Med. 1988 May;88(5):278–279. [PubMed]
  • Sobel JD, Vazquez J, Lynch M, Meriwether C, Zervos MJ. Vaginitis due to Saccharomyces cerevisiae: epidemiology, clinical aspects, and therapy. Clin Infect Dis. 1993 Jan;16(1):93–99. [PubMed]
  • Tawfik OW, Papasian CJ, Dixon AY, Potter LM. Saccharomyces cerevisiae pneumonia in a patient with acquired immune deficiency syndrome. J Clin Microbiol. 1989 Jul;27(7):1689–1691. [PMC free article] [PubMed]
  • Tiballi RN, Spiegel JE, Zarins LT, Kauffman CA. Saccharomyces cerevisiae infections and antifungal susceptibility studies by colorimetric and broth macrodilution methods. Diagn Microbiol Infect Dis. 1995 Dec;23(4):135–140. [PubMed]
  • Wilson JD, Jones BM, Kinghorn GR. Bread-making as a source of vaginal infection with Saccharomyces cerevisiae. Report of a case in a woman and apparent transmission to her partner. Sex Transm Dis. 1988 Jan-Mar;15(1):35–36. [PubMed]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...